ADD/ADHD News

Recent findings did not indicate a causal association between methylphenidate treatment and suicide attempts.

Impax Laboratories recently announced receipt of an AB therapeutic equivalent rating and final FDA approval for its abbreviated New Drug Application for a generic version of extended-release Concerta for ADHD.

ADHD medication treatment was not associated with increased risk for substance-related problems in adolescence or adulthood, according to study results.

Newly licensed adolescents with attention-deficit/hyperactivity disorder are 1.36 times more likely to experience a vehicular crash than teenagers without the condition, according to a study published in JAMA Pediatrics.

ADHD medication use was associated with better performance on higher education entrance tests among individuals with ADHD, according to recent findings.

The FDA recently approved Mydayis, a once-daily mixed salts of a single-entity amphetamine product from Shire, for treatment of ADHD in individuals aged 13 years and older.

Autism was associated with an increased risk for violent crime; however, the association was significantly attenuated by comorbid ADHD or conduct disorder, according to recent findings.

Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged 6 to 17 years.

Black and Hispanic children enrolled in Medicaid are significantly more likely to discontinue pharmacological treatment for attention-deficit/hyperactivity disorder when compared with Medicaid-enrolled white children, according to study results.

The FDA today approved the first generic of Strattera for treatment of ADHD in children and adults.